358 related articles for article (PubMed ID: 17589527)
1. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
Imhof A; Balajee SA; Fredricks DN; Englund JA; Marr KA
Clin Infect Dis; 2004 Sep; 39(5):743-6. PubMed ID: 15356792
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.
Trifilio S; Ortiz R; Pennick G; Verma A; Pi J; Stosor V; Zembower T; Mehta J
Bone Marrow Transplant; 2005 Mar; 35(5):509-13. PubMed ID: 15654347
[TBL] [Abstract][Full Text] [Related]
5. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
Trifilio S; Pennick G; Pi J; Zook J; Golf M; Kaniecki K; Singhal S; Williams S; Winter J; Tallman M; Gordon L; Frankfurt O; Evens A; Mehta J
Cancer; 2007 Apr; 109(8):1532-5. PubMed ID: 17351937
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
7. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
Siwek GT; Dodgson KJ; de Magalhaes-Silverman M; Bartelt LA; Kilborn SB; Hoth PL; Diekema DJ; Pfaller MA
Clin Infect Dis; 2004 Aug; 39(4):584-7. PubMed ID: 15356827
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.
Marty FM; Cosimi LA; Baden LR
N Engl J Med; 2004 Feb; 350(9):950-2. PubMed ID: 14985500
[No Abstract] [Full Text] [Related]
9. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole -- better chances for patients with invasive mycoses.
Ghannoum MA; Kuhn DM
Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
Trifilio SM; Bennett CL; Yarnold PR; McKoy JM; Parada J; Mehta J; Chamilos G; Palella F; Kennedy L; Mullane K; Tallman MS; Evens A; Scheetz MH; Blum W; Kontoyiannis DP
Bone Marrow Transplant; 2007 Apr; 39(7):425-9. PubMed ID: 17310132
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
[TBL] [Abstract][Full Text] [Related]
14. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.
Cordonnier C; Maury S; Pautas C; Bastié JN; Chehata S; Castaigne S; Kuentz M; Bretagne S; Ribaud P
Bone Marrow Transplant; 2004 May; 33(9):943-8. PubMed ID: 15034546
[TBL] [Abstract][Full Text] [Related]
15. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough Candida infections in patients receiving voriconazole.
Gerzenshtein L; Patel SM; Scarsi KK; Postelnick MJ; Flaherty JP
Ann Pharmacother; 2005; 39(7-8):1342-5. PubMed ID: 15914520
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
18. [Voriconazole: a new weapon against invasive fungal infections].
Aoun M
Rev Med Brux; 2004 Jun; 25(3):166-71. PubMed ID: 15291449
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of new antifungal agents.
Kauffman CA
Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366
[TBL] [Abstract][Full Text] [Related]
20. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
